Share Price and Basic Stock Data
Last Updated: November 22, 2025, 8:44 am
| PEG Ratio | -0.71 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Hemant Surgical Industries Ltd operates within the medical equipment and accessories sector, as evidenced by its reported revenue figures. For the financial year ending March 2025, the company recorded sales of ₹107 Cr, which represents a slight decline from ₹109 Cr in the previous year. However, the trailing twelve-month (TTM) revenue reached ₹122 Cr, indicating a positive growth trajectory in the most recent quarter. Analyzing quarterly sales, the company reported ₹58 Cr in March 2024, consistent with its March 2023 sales of ₹58 Cr, but showed a dip to ₹48 Cr in September 2023. Over the years, sales have increased from ₹51 Cr in March 2018 to ₹107 Cr in March 2025, showcasing a steady upward trend despite minor fluctuations. This growth reflects the company’s ability to capitalize on the expanding healthcare sector, which is projected to grow due to rising healthcare demands and technological advancements.
Profitability and Efficiency Metrics
Hemant Surgical Industries reported an operating profit margin (OPM) of 10% for the year ending March 2025, reflecting a stable performance compared to an OPM of 10% in the previous year. The company’s net profit for the same period stood at ₹8 Cr, down from ₹10 Cr in the prior year, primarily due to increased operational expenses. The interest coverage ratio (ICR) remained robust at 6.40x, indicating strong earnings relative to interest obligations. Meanwhile, return on equity (ROE) was reported at 13.6%, and return on capital employed (ROCE) was 16.4%, both of which align well with sector averages. The cash conversion cycle (CCC) of 87 days suggests that the company is efficiently managing its working capital, although it has seen an increase from 15 days in the previous year. Overall, while profitability metrics indicate some challenges, the company maintains a solid foundation for operational efficiency.
Balance Sheet Strength and Financial Ratios
As of March 2025, Hemant Surgical Industries reported total assets of ₹148 Cr, up from ₹100 Cr in the previous year, illustrating a robust asset base. Total liabilities also increased to ₹148 Cr, driven by borrowings that rose to ₹31 Cr from ₹7 Cr in the previous year. The company’s reserves stood at ₹53 Cr, reflecting a healthy accumulation of retained earnings. The current ratio was reported at 1.45x, indicating sufficient liquidity to cover short-term liabilities. Furthermore, the debt-to-equity ratio was recorded at 0.49x, suggesting a moderate level of leverage. This financial structure denotes a balanced approach to financing growth while maintaining control of debt levels. The price-to-book value ratio (P/BV) stood at 1.65x, indicating that the market values the company at a premium to its book value, reflecting investor confidence in its long-term growth potential.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Hemant Surgical Industries as of September 2025 reveals a significant promoter holding of 58.90%, which is a decrease from 73.56% in September 2023. This shift may indicate a dilution of control as the company seeks to attract more public investment. Foreign institutional investors (FIIs) held a mere 0.15%, while domestic institutional investors (DIIs) accounted for 10.81%, a notable increase from previous quarters. The public shareholding has risen to 30.13%, highlighting growing interest from retail investors. The total number of shareholders stood at 758 as of September 2025, a decrease from 1,229 in March 2025, suggesting some volatility in investor sentiment. The high promoter holding indicates confidence in the company’s direction, yet the decline in their stake may raise questions about future governance and control.
Outlook, Risks, and Final Insight
Looking ahead, Hemant Surgical Industries is well-positioned to benefit from the increasing demand for medical equipment, driven by advancements in healthcare technology and a growing population. However, the company faces several risks, including rising operational costs that could impact profitability and a high dependency on domestic markets for revenue. Additionally, the fluctuating shareholding pattern may affect investor confidence and stock performance. If the company can stabilize its expenses and maintain its operational efficiency, it could enhance profitability and shareholder value. Conversely, challenges such as regulatory changes or increased competition could hinder growth. The balance between leveraging growth opportunities and managing risks will be critical for the company’s sustained success in the competitive medical equipment sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Hemant Surgical Industries Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Hemant Surgical Industries Ltd | 359 Cr. | 275 | 367/88.2 | 34.6 | 94.3 | 0.00 % | 16.4 % | 13.6 % | 10.0 |
| Industry Average | 359.00 Cr | 275.00 | 34.60 | 94.30 | 0.00% | 16.40% | 13.60% | 10.00 |
Quarterly Result
| Metric | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Sales | 51 | 58 | 48 | 58 | 49 | 58 |
| Expenses | 47 | 52 | 44 | 51 | 45 | 52 |
| Operating Profit | 4 | 6 | 3 | 7 | 4 | 6 |
| OPM % | 8% | 11% | 7% | 13% | 7% | 10% |
| Other Income | 1 | 1 | 3 | 2 | 2 | 3 |
| Interest | 1 | 1 | 1 | 0 | 1 | 1 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit before tax | 4 | 6 | 5 | 8 | 4 | 6 |
| Tax % | 36% | 18% | 17% | 27% | 29% | 18% |
| Net Profit | 2 | 5 | 4 | 6 | 3 | 5 |
| EPS in Rs | 48.12 | 6.93 | 3.75 | 5.63 | 3.05 | 4.74 |
Last Updated: May 31, 2025, 8:57 am
Below is a detailed analysis of the quarterly data for Hemant Surgical Industries Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 58.00 Cr.. The value appears strong and on an upward trend. It has increased from 49.00 Cr. (Sep 2024) to 58.00 Cr., marking an increase of 9.00 Cr..
- For Expenses, as of Mar 2025, the value is 52.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 45.00 Cr. (Sep 2024) to 52.00 Cr., marking an increase of 7.00 Cr..
- For Operating Profit, as of Mar 2025, the value is 6.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Sep 2024) to 6.00 Cr., marking an increase of 2.00 Cr..
- For OPM %, as of Mar 2025, the value is 10.00%. The value appears strong and on an upward trend. It has increased from 7.00% (Sep 2024) to 10.00%, marking an increase of 3.00%.
- For Other Income, as of Mar 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Sep 2024) to 3.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Mar 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 1.00 Cr..
- For Depreciation, as of Mar 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 1.00 Cr..
- For Profit before tax, as of Mar 2025, the value is 6.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Sep 2024) to 6.00 Cr., marking an increase of 2.00 Cr..
- For Tax %, as of Mar 2025, the value is 18.00%. The value appears to be improving (decreasing) as expected. It has decreased from 29.00% (Sep 2024) to 18.00%, marking a decrease of 11.00%.
- For Net Profit, as of Mar 2025, the value is 5.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Sep 2024) to 5.00 Cr., marking an increase of 2.00 Cr..
- For EPS in Rs, as of Mar 2025, the value is 4.74. The value appears strong and on an upward trend. It has increased from 3.05 (Sep 2024) to 4.74, marking an increase of 1.69.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 5:12 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 56 | 56 | 60 | 101 | 109 | 106 | 107 | 122 |
| Expenses | 48 | 53 | 53 | 57 | 95 | 98 | 95 | 97 | 109 |
| Operating Profit | 2 | 3 | 3 | 3 | 6 | 11 | 10 | 9 | 13 |
| OPM % | 5% | 5% | 5% | 5% | 6% | 10% | 10% | 9% | 11% |
| Other Income | 0 | 0 | 0 | 1 | 2 | 2 | 4 | 5 | 5 |
| Interest | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 3 |
| Depreciation | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 1 | 1 | 1 | 6 | 10 | 13 | 11 | 13 |
| Tax % | 10% | 8% | 41% | 9% | 25% | 24% | 23% | 23% | |
| Net Profit | 1 | 1 | 0 | 1 | 5 | 8 | 10 | 8 | 10 |
| EPS in Rs | 50.76 | 61.02 | 27.00 | 73.43 | 248.92 | 9.95 | 9.39 | 7.79 | 8.89 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | -100.00% | 400.00% | 60.00% | 25.00% | -20.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -100.00% | 500.00% | -340.00% | -35.00% | -45.00% |
Hemant Surgical Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2018-2019 to 2024-2025.
Growth
Last Updated: September 5, 2025, 6:30 am
Balance Sheet
Last Updated: October 10, 2025, 2:12 pm
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 8 | 10 | 10 |
| Reserves | 5 | 6 | 5 | 8 | 11 | 16 | 44 | 53 |
| Borrowings | 9 | 11 | 14 | 14 | 10 | 7 | 7 | 31 |
| Other Liabilities | 12 | 14 | 23 | 15 | 32 | 34 | 38 | 54 |
| Total Liabilities | 28 | 33 | 44 | 40 | 54 | 65 | 100 | 148 |
| Fixed Assets | 7 | 8 | 10 | 11 | 12 | 13 | 18 | 40 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 |
| Investments | 0 | 0 | 1 | 0 | 1 | 0 | 5 | 1 |
| Other Assets | 21 | 25 | 33 | 29 | 42 | 51 | 77 | 94 |
| Total Assets | 28 | 33 | 44 | 40 | 54 | 65 | 100 | 148 |
Below is a detailed analysis of the balance sheet data for Hemant Surgical Industries Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 10.00 Cr..
- For Reserves, as of Mar 2025, the value is 53.00 Cr.. The value appears strong and on an upward trend. It has increased from 44.00 Cr. (Mar 2024) to 53.00 Cr., marking an increase of 9.00 Cr..
- For Borrowings, as of Mar 2025, the value is 31.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 7.00 Cr. (Mar 2024) to 31.00 Cr., marking an increase of 24.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 54.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 38.00 Cr. (Mar 2024) to 54.00 Cr., marking an increase of 16.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 148.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 100.00 Cr. (Mar 2024) to 148.00 Cr., marking an increase of 48.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 40.00 Cr.. The value appears strong and on an upward trend. It has increased from 18.00 Cr. (Mar 2024) to 40.00 Cr., marking an increase of 22.00 Cr..
- For CWIP, as of Mar 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 12.00 Cr., marking an increase of 12.00 Cr..
- For Investments, as of Mar 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5.00 Cr. (Mar 2024) to 1.00 Cr., marking a decrease of 4.00 Cr..
- For Other Assets, as of Mar 2025, the value is 94.00 Cr.. The value appears strong and on an upward trend. It has increased from 77.00 Cr. (Mar 2024) to 94.00 Cr., marking an increase of 17.00 Cr..
- For Total Assets, as of Mar 2025, the value is 148.00 Cr.. The value appears strong and on an upward trend. It has increased from 100.00 Cr. (Mar 2024) to 148.00 Cr., marking an increase of 48.00 Cr..
Notably, the Reserves (53.00 Cr.) exceed the Borrowings (31.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -7.00 | -8.00 | -11.00 | -11.00 | -4.00 | 4.00 | 3.00 | -22.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 35 | 36 | 35 | 26 | 56 | 58 | 75 | 70 |
| Inventory Days | 64 | 73 | 125 | 113 | 57 | 67 | 99 | 205 |
| Days Payable | 102 | 97 | 143 | 89 | 92 | 110 | 116 | 188 |
| Cash Conversion Cycle | -3 | 12 | 17 | 51 | 21 | 15 | 58 | 87 |
| Working Capital Days | 12 | 23 | -28 | 41 | -19 | 2 | 52 | 61 |
| ROCE % | 15% | 12% | 14% | 32% | 45% | 30% | 16% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 |
|---|---|
| FaceValue | 10.00 |
| Basic EPS (Rs.) | 7.70 |
| Diluted EPS (Rs.) | 7.70 |
| Cash EPS (Rs.) | 9.07 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 60.51 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 60.51 |
| Revenue From Operations / Share (Rs.) | 102.14 |
| PBDIT / Share (Rs.) | 13.50 |
| PBIT / Share (Rs.) | 12.14 |
| PBT / Share (Rs.) | 10.02 |
| Net Profit / Share (Rs.) | 7.70 |
| NP After MI And SOA / Share (Rs.) | 7.70 |
| PBDIT Margin (%) | 13.21 |
| PBIT Margin (%) | 11.88 |
| PBT Margin (%) | 9.81 |
| Net Profit Margin (%) | 7.54 |
| NP After MI And SOA Margin (%) | 7.54 |
| Return on Networth / Equity (%) | 12.72 |
| Return on Capital Employeed (%) | 14.55 |
| Return On Assets (%) | 5.42 |
| Long Term Debt / Equity (X) | 0.36 |
| Total Debt / Equity (X) | 0.49 |
| Current Ratio (X) | 1.45 |
| Quick Ratio (X) | 0.74 |
| Interest Coverage Ratio (X) | 6.40 |
| Interest Coverage Ratio (Post Tax) (X) | 4.65 |
| Enterprise Value (Cr.) | 125.52 |
| EV / Net Operating Revenue (X) | 1.18 |
| EV / EBITDA (X) | 8.90 |
| MarketCap / Net Operating Revenue (X) | 0.97 |
| Price / BV (X) | 1.65 |
| Price / Net Operating Revenue (X) | 0.97 |
| EarningsYield | 0.07 |
After reviewing the key financial ratios for Hemant Surgical Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
- For Basic EPS (Rs.), as of Mar 25, the value is 7.70. This value is within the healthy range. No previous period data is available for comparison.
- For Diluted EPS (Rs.), as of Mar 25, the value is 7.70. This value is within the healthy range. No previous period data is available for comparison.
- For Cash EPS (Rs.), as of Mar 25, the value is 9.07. This value is within the healthy range. No previous period data is available for comparison.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 60.51. No previous period data is available for comparison.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 60.51. No previous period data is available for comparison.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 102.14. No previous period data is available for comparison.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 13.50. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.14. This value is within the healthy range. No previous period data is available for comparison.
- For PBT / Share (Rs.), as of Mar 25, the value is 10.02. This value is within the healthy range. No previous period data is available for comparison.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 7.70. This value is within the healthy range. No previous period data is available for comparison.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 7.70. This value is within the healthy range. No previous period data is available for comparison.
- For PBDIT Margin (%), as of Mar 25, the value is 13.21. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT Margin (%), as of Mar 25, the value is 11.88. This value is within the healthy range. No previous period data is available for comparison.
- For PBT Margin (%), as of Mar 25, the value is 9.81. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Net Profit Margin (%), as of Mar 25, the value is 7.54. This value is within the healthy range. No previous period data is available for comparison.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.54. This value is below the healthy minimum of 8. No previous period data is available for comparison.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.72. This value is below the healthy minimum of 15. No previous period data is available for comparison.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.55. This value is within the healthy range. No previous period data is available for comparison.
- For Return On Assets (%), as of Mar 25, the value is 5.42. This value is within the healthy range. No previous period data is available for comparison.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.36. This value is within the healthy range. No previous period data is available for comparison.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.49. This value is within the healthy range. No previous period data is available for comparison.
- For Current Ratio (X), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 1.5. No previous period data is available for comparison.
- For Quick Ratio (X), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 6.40. This value is within the healthy range. No previous period data is available for comparison.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.65. This value is within the healthy range. No previous period data is available for comparison.
- For Enterprise Value (Cr.), as of Mar 25, the value is 125.52. No previous period data is available for comparison.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.18. This value is within the healthy range. No previous period data is available for comparison.
- For EV / EBITDA (X), as of Mar 25, the value is 8.90. This value is within the healthy range. No previous period data is available for comparison.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.97. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For Price / BV (X), as of Mar 25, the value is 1.65. This value is within the healthy range. No previous period data is available for comparison.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.97. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For EarningsYield, as of Mar 25, the value is 0.07. This value is below the healthy minimum of 5. No previous period data is available for comparison.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Hemant Surgical Industries Ltd:
- Net Profit Margin: 7.54%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.55% (Industry Average ROCE: 16.4%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.72% (Industry Average ROE: 13.6%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.65
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.74
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 34.6 (Industry average Stock P/E: 34.6)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.49
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.54%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Equipment & Accessories | 502, 5th Floor, Ecstasy Business Park Co-Op Socteiy Limited, Mumbai Maharashtra 400080 | info@hemantsurgical.com http://www.hemantsurgical.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Hanskumar Shah | Chairman & Managing Director |
| Mr. Kaushik Hanskumar Shah | WholeTime Director & CFO |
| Mr. Hemant Praful Shah | Whole Time Director |
| Mrs. Nehal Babu Karelia | Non Executive Director |
| Mr. Ketan Chandrakat Dave | Independent Director |
| Mrs. Kshama Dharnidharka | Independent Director |
FAQ
What is the intrinsic value of Hemant Surgical Industries Ltd?
Hemant Surgical Industries Ltd's intrinsic value (as of 25 November 2025) is 362.09 which is 31.67% higher the current market price of 275.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 359 Cr. market cap, FY2025-2026 high/low of 367/88.2, reserves of ₹53 Cr, and liabilities of 148 Cr.
What is the Market Cap of Hemant Surgical Industries Ltd?
The Market Cap of Hemant Surgical Industries Ltd is 359 Cr..
What is the current Stock Price of Hemant Surgical Industries Ltd as on 25 November 2025?
The current stock price of Hemant Surgical Industries Ltd as on 25 November 2025 is 275.
What is the High / Low of Hemant Surgical Industries Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Hemant Surgical Industries Ltd stocks is 367/88.2.
What is the Stock P/E of Hemant Surgical Industries Ltd?
The Stock P/E of Hemant Surgical Industries Ltd is 34.6.
What is the Book Value of Hemant Surgical Industries Ltd?
The Book Value of Hemant Surgical Industries Ltd is 94.3.
What is the Dividend Yield of Hemant Surgical Industries Ltd?
The Dividend Yield of Hemant Surgical Industries Ltd is 0.00 %.
What is the ROCE of Hemant Surgical Industries Ltd?
The ROCE of Hemant Surgical Industries Ltd is 16.4 %.
What is the ROE of Hemant Surgical Industries Ltd?
The ROE of Hemant Surgical Industries Ltd is 13.6 %.
What is the Face Value of Hemant Surgical Industries Ltd?
The Face Value of Hemant Surgical Industries Ltd is 10.0.